申请人:Hoffmann-La Roche Inc.
公开号:US05238962A1
公开(公告)日:1993-08-24
Benzamides of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently is hydrogen, halogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, sulfamoyl, mono(lower alkyl)sulfamoyl or di(lower alkyl)sulfamoyl or R.sup.1 and R.sup.2 on adjacent carbon atoms together are a methylenedioxy group, with the proviso that R.sup.2 is different from hydrogen when R.sup.1 are bromine in the 3-position, and their pharmaceutically acceptable acid addition salts have monoamine oxidase inhibiting properties with low toxicity and can accordingly be used for the treatment of depressive states and Parkinsonism.
式为 ##STR1## 的苯甲酰胺,其中R.sup.1和R.sup.2各自独立地是氢、卤素、较低的烷基、较低的烷氧基、氰基、三氟甲基、磺酰氨基、单(较低的烷基)磺酰氨基或二(较低的烷基)磺酰氨基,或者R.sup.1和R.sup.2在相邻的碳原子上一起形成亚甲二氧基基团,但R.sup.1为溴在3位时,R.sup.2不同于氢,其药学上可接受的酸加盐具有低毒性的单胺氧化酶抑制作用,因此可用于治疗抑郁症和帕金森病。